Stockreport

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and S [Read more]